LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.

NCT Number	NCT07408531
Lead Sponsor	University of Illinois at Chicago Collaborators: Eli Lilly and Company
Conditions	Lung Cancer Screening
Enrollment	2,500 participants
Start Date	2026-03-12
Primary Completion	2028-03 (estimated)
Study Completion	2038-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-06